MHE Week in Review – U.S. AIDS Support Turmoil, Life After Double Mastectomy and More

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks associated with taking the medication.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Two-thirds of high severity likely due to upcoding, according to a RAND study of hospitalizations in five states.

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.